A combined approach including EMT and/or stemness targets and target therapies might reduce tumor relapse and progression in several cancers, such as HER-2-positive breast cancer, in which cancer progression is often linked to acquired EMT and stemness features [116,124,125,126,127]. Here, ERBB2 is linked to neoplasm.